Mr Mrs Miss Ms Dr Other

Dr
Robert
Scanes

Patent Attorney

London Office

Chemistry

Telephone. +44(0) 207 776 5100
Email. rscanes@hgf.com
Vcard

Experience

Robert specialises in patents and related IP rights in the fields of chemistry, pharmaceuticals and biotechnology.

He has broad experience in patent practice, including urgent drafting for SARS-CoV-2 antivirals during the COVID-19 pandemic, coordinating global patent portfolios for a pharmaceutical candidate in phase III clinical trials and contentious proceedings before the European Patent Office defending market exclusivity determining patents for authorised drugs. Robert also provides advice regarding freedom-to-operate and validity.

He is familiar with the differing needs of prosecuting applications in several fields, encompassing consumer goods, graphene technology and polymer chemistry.

Robert's technical experience spans the interface between chemistry and biology, working on new chemical entity, polymorphic form, dosage regimen and subsequent medical use cases.

Before joining the profession Robert discovered a new oscillating chemical reaction during his doctoral research, work that was highlighted in the journal Science. His laboratory work reflected his long-held interests in enantioselective catalysis, non-linear reaction kinetics, protocell movement, oligonucleotide modification and super-resolution microscopy. He holds a first class Master's degree in Natural Sciences from the University of Cambridge, where he was awarded scholarships and bursaries for academic performance.

Specialisms

Industries

Services

Qualifications

Patent Attorney

Chartered (UK)
Europe

BA

BA in Natural Sciences, First Class, University of Cambridge

MSCI

Natural Sciences, First Class, University of Cambridge

POSTGRADUATE DIPLOMA OR CERTIFICATE

Intellectual Property Law, Distinction, Queen Mary University of London

OTHER

DPhil in Organic Chemistry, Thesis Title "Selection among Replicators and Protocell Chemotaxis", University of Oxford

Publications

UPC delivers first judgment on Validity and Infringement of a Second Medical Use Claim

View publication online

T 0295/22: Apremilast decision highlights hopes and challenges for broad second medical use claims

View publication online

T 1418/22: Acalabrutinib provides guidance on establishing inventiveness of polymorphs at the EPO

View publication online

Related News

Event - 2nd - 6th May 2026

INTA 2026 Annual Meeting

HGF’s European team are delighted to be attending the INTA Annual Meeting 2026, taking place from 2nd-6th May in London. As one of Europe’s leading IP firms, HGF brings together …

Event details
Event - 25th March 2026

HGF Women IP Inclusive Event

HGF are hosting Connected Bubbles Networking Event on Wednesday 25 March 2026 and this year they are teaming up with CIPA! In a profession built on collaboration, referrals and trusted …

Event details
Event - 16th, 17th March 2026

HGF are sponsors of IQPC Europe 2026

HGF is proud to sponsor IQPC’s Global IP Exchange Europe 2026, an exclusive invite-only forum bringing together senior in-house IP decision makers from across Europe. In a landscape shaped by …

Event details
Event - 23rd - 25th March 2026

HGF are Gold Sponsors of IPBC Europe 2026

HGF are proud sponsors of IPBC Europe 2026, taking place from 23-25 March 2026 at the Pullman Paris Montparnasse. Bringing together patent pioneers, in-house leaders and private practice specialists, IPBC …

Event details
Event - 8th - 11th February 2026

AUTM Meeting 2026

We are attending the AUTM Annual Meeting from 8–11 February, a flagship event bringing together technology transfer professionals from across the globe. AUTM connects innovators, universities, and industry leaders to …

Event details
Event - 3rd February 2026

HGF Brand & Design Conference 2026

Join us on 3rd February 2026 for HGF’s Brand & Design Conference, the must attend event for in-house legal teams, brand leaders, creatives, and innovators shaping the future of IP. …

Event details
See all updates

Let's talk

If you would like to discuss how HGF could help you, contact one of our IP specialists.

Contact us